Carol Webb Net Worth

The estimated Net Worth of Carol Webb is at least $6.4 millier dollars as of 4 March 2024. Ms. Webb owns over 12,071 units of Citius Pharmaceuticals Inc stock worth over $6,398 and over the last 8 years she sold CTXR stock worth over $0. In addition, she makes $0 as Independent Director at Citius Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Webb CTXR stock SEC Form 4 insiders trading

Carol has made over 1 trades of the Citius Pharmaceuticals Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently she exercised 12,071 units of CTXR stock worth $241 on 4 March 2024.

The largest trade she's ever made was exercising 12,071 units of Citius Pharmaceuticals Inc stock on 4 March 2024 worth over $241. On average, Carol trades about 1,006 units every 0 days since 2016. As of 4 March 2024 she still owns at least 12,071 units of Citius Pharmaceuticals Inc stock.

You can see the complete history of Ms. Webb stock trades at the bottom of the page.

Carol Webb biography

Carol A. Webb serves as Independent Director of the Company. Ms. Webb has served as a director of LMB and, upon LMB’s acquisition by the Company in March 2016, a director of the Company. From 2000 to 2005, she served as Company Group Chairman of Johnson & Johnson, and from 1987 to 2000 she served in capacities including President, Vice President, Executive Director, Product Management and Senior Product Director of Ortho Biotech. Ms. Webb has worked in various positions including Sales Representative, Sales Trainer, Product Manager and Manager of Public Policy at Roche Laboratories from 1972 to 1983. Ms. Webb received her B.S. in Biology from Bowling Green State University.

How old is Carol Webb?

Carol Webb is 73, she's been the Independent Director of Citius Pharmaceuticals Inc since 2016. There are 5 older and 7 younger executives at Citius Pharmaceuticals Inc. The oldest executive at Citius Pharmaceuticals Inc is Suren Dutia, 77, who is the Independent Director.

What's Carol Webb's mailing address?

Carol's mailing address filed with the SEC is C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD, NJ, 07016.

Insiders trading at Citius Pharmaceuticals Inc

Over the last 9 years, insiders at Citius Pharmaceuticals Inc have traded over $0 worth of Citius Pharmaceuticals Inc stock and bought 13,825,289 units worth $15,819,221 . The most active insiders traders include Leonard L Mazur, Myron Z Holubiak et Dennis M Mcgrath. On average, Citius Pharmaceuticals Inc executives and independent directors trade stock every 207 days with the average trade being worth of $523,934. The most recent stock trade was executed by Eugene Myron Holuka on 13 March 2024, trading 2,415 units of CTXR stock currently worth $48.

What does Citius Pharmaceuticals Inc do?

citius pharmaceuticals, inc., a specialty pharmaceutical company, develops and commercializes critical care products. it primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. the company is developing mino-lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in phase iii clinical trials; mino-wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; halo-lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and novecite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. citius pharmaceuticals, inc. was founded in 2007 and is headquartered in cranford, new jersey.

Complete history of Ms. Webb stock trades at Citius Pharmaceuticals Inc

Citius Pharmaceuticals Inc executives and stock owners

Citius Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Myron Z. Holubiak,
  Pres, CEO & Director
• Myron Holubiak,
  President, Chief Executive Officer, Director
• Leonard L. Mazur,
  Exec. Chairman & Sec.
• Dr. Myron S. Czuczman M.D.,
  Exec. VP & Chief Medical Officer
• Jaime Bartushak,
  Chief Financial Officer, Principal Financial Officer
• Jaime Bartushak,
  CFO & Chief Accounting Officer
• Leonard Mazur,
  Executive Chairman of the Board, Secretary
• Carol Webb,
  Independent Director
• Howard Safir,
  Independent Director
• William Kane,
  Independent Director
• Eugene Holuka,
  Independent Director
• Suren Dutia,
  Independent Director
• Kelly Creighton Ph.D.,
  Exec. VP of Chemistry, Manufacturing & Controls
• Dhananjay G. Wadekar,
  Sr. VP of Bus. Strategy
• Ilanit Allen,
  VP of Investor Relations
• Gary F. Talarico,
  Exec. VP of Operations
• Myron Czuczman,
  Chief Medical Officer
• Robert Joseph Smith,
  Director
• Dennis M Mcgrath,
  Director